These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 19368100

  • 1. Insulin therapy in type 2 diabetes for physicians and practitioners.
    Das AK.
    J Indian Med Assoc; 2008 Nov; 106(11):741-2, 744-6. PubMed ID: 19368100
    [Abstract] [Full Text] [Related]

  • 2. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 3. [Recommendations concerning the initial regimen and dose adjustments of insulin therapy for type 2 diabetes mellitus].
    Houweling ST, Timmerman GJ, Hoogstraten MF, Ubink-Veltmaat LJ, Verhoeven S, Bilo HJ.
    Ned Tijdschr Geneeskd; 2002 Sep 28; 146(39):1823-7. PubMed ID: 12382366
    [Abstract] [Full Text] [Related]

  • 4. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes.
    Crasto W, Jarvis J, Khunti K, Davies MJ.
    Postgrad Med J; 2009 May 28; 85(1003):257-67. PubMed ID: 19520878
    [Abstract] [Full Text] [Related]

  • 5. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec 28; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 6. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.
    Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration.
    QJM; 2007 Jun 28; 100(6):345-50. PubMed ID: 17504861
    [Abstract] [Full Text] [Related]

  • 7. Perspectives in type 2 diabetes: incorporating the latest insulin analogue strategies to achieve treatment success.
    Diabetes Obes Metab; 2009 Nov 28; 11 Suppl 5():iii-iv. PubMed ID: 19817775
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Optimal initiation of insulin in type 2 diabetes.
    Hirsch IB, Vega CP.
    MedGenMed; 2005 Nov 16; 7(4):49. PubMed ID: 16614671
    [Abstract] [Full Text] [Related]

  • 10. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C, Shimizu T, Arakawa M, Mita T, Fujitani Y, Watada H, Kawamori R, Hirose T.
    Diabetes Res Clin Pract; 2009 Oct 16; 86(1):31-6. PubMed ID: 19692134
    [Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
    Monami M, Lamanna C, Marchionni N, Mannucci E.
    Exp Clin Endocrinol Diabetes; 2009 May 16; 117(5):220-2. PubMed ID: 19301231
    [Abstract] [Full Text] [Related]

  • 12. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 16; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 13. [The increase in the use of drug treatment for diabetes mellitus in the Netherlands, 1998-2003].
    Langendam MW, Hooijkaas C, Piepenbrink JF.
    Ned Tijdschr Geneeskd; 2006 Jun 24; 150(25):1396-401. PubMed ID: 16841589
    [Abstract] [Full Text] [Related]

  • 14. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C, Gilbride CJ.
    Diabetes Obes Metab; 2008 Jul 24; 10 Suppl 2():50-65. PubMed ID: 18577157
    [Abstract] [Full Text] [Related]

  • 15. Insulin in type 2 diabetes: promises to keep.
    Basu AK, Bandyopadhyay D, Bandyopadhyay R, Majumdar D, Chakrabarty PP.
    J Indian Med Assoc; 2004 Aug 24; 102(8):438, 440, 442 passim. PubMed ID: 15719806
    [Abstract] [Full Text] [Related]

  • 16. U-500 insulin: why, when and how to use in clinical practice.
    Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG.
    Diabetes Metab Res Rev; 2007 May 24; 23(4):265-8. PubMed ID: 17109474
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Starting insulin therapy for type-2 diabetes.
    Harbuwono DS.
    Acta Med Indones; 2010 Apr 24; 42(2):116-20. PubMed ID: 20513939
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Addressing barriers to initiation of insulin in patients with type 2 diabetes.
    Peyrot M, Rubin RR, Khunti K.
    Prim Care Diabetes; 2010 Apr 24; 4 Suppl 1():S11-8. PubMed ID: 20394886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.